Insmed has moved 160.1% over the last year, and the S&P 500 logged a change of 8.1% INSM has an average analyst rating of buy ...

The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...

United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food ...

PRINT enabled the creation of Liquidia's lead candidate, YUTREPIA (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...

Following the presentations, each poster will be available on the Publications page of Liquidia's website at https://liquidia.com/publications.

Commonwealth Equity Services LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 3.7% during ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder ...

Revenue decreased by $3.5 million in 2024 compared to 2023, attributed to lower sales quantities linked to limitations on the availability of necessary pumps for administering Treprostinil Injection.

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025 Advancing pipeline of inhaled treprostinil products in clinical studies Strengthened financial ...